CN Patent

CN113577066B — 芳基胍化合物或其药学上可接受的盐的用途

Assigned to Shanghai Institute of Materia Medica of CAS · Expires 2022-12-16 · 3y expired

What this patent protects

本发明涉及式1所示的芳基胍化合物或其药学上可接受的盐的用途，具体地，本发明涉及一种如式1所示的芳基胍化合物或其药学上可接受的盐在制备预防或治疗新生血管生成相关眼科疾病的药物中的用途。

USPTO Abstract

本发明涉及式1所示的芳基胍化合物或其药学上可接受的盐的用途，具体地，本发明涉及一种如式1所示的芳基胍化合物或其药学上可接受的盐在制备预防或治疗新生血管生成相关眼科疾病的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN113577066B
Jurisdiction
CN
Classification
—
Expires
2022-12-16
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Institute of Materia Medica of CAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.